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a  b  s  t  r  a  c  t
NetB  (necrotic  enteritis  toxin  B)  is a recently  identiﬁed  -pore-forming  toxin  produced  by Clostridium
perfringens.  This  toxin  has  been  shown  to play  a major  role  in  avian  necrotic  enteritis.  In recent  years,
a  dramatic  increase  in necrotic  enteritis  has  been  observed,  especially  in  countries  where  the  use  of
antimicrobial  growth  promoters  in  animal  feedstuffs  has  been  banned.  The aim of this  work  was  to
determine  whether  immunisation  with a NetB  toxoid would  provide  protection  against  necrotic  enteritis.
The immunisation  of poultry  with  a formaldehyde  NetB  toxoid  or with  a NetB  genetic  toxoid  (W262A)eywords:
lostridium perfringens
etB
ore-forming toxin
ecrotic enteritis
hicken
resulted  in  the  induction  of  antibody  responses  against  NetB  and  provided  partial  protection  against
disease.
© 2013 The Authors. Published by Elsevier Ltd. All rights reserved.accine
. Introduction
Clostridium perfringens (C. perfringens) is a ubiquitous bacterium
hat is able to colonise a variety of different biotopes and it is not
nusual to ﬁnd C. perfringens as a commensal in the normal gut
icrobiota in domesticated animals. However, under particular cir-
umstances the bacterium is responsible for severe diseases. These
iseases are largely a consequence of the actions of toxins on the
ost [1]. In addition to the four toxins used for typing C. perfrin-
ens strains (alpha-, beta-, epsilon-, and iota-toxin), the bacterium
s able to produce a number of other toxins, including enterotoxin
nd perfringolysin O [2,3].
C. perfringens has been shown to cause avian necrotic enteri-
is (NE), a severe gastro-intestinal disease of farmed poultry [4–6].
ntil recently, NE has been controlled by the addition of antimicro-
ial growth promoters to feedstuffs. However, in many countries
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on-commercial use, distribution, and reproduction in any medium, provided the
riginal author and source are credited.
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ttp://dx.doi.org/10.1016/j.vaccine.2013.05.063national and supranational regulations now limit the addition of
antimicrobials to animal feeds. Consequently, in these countries,
NE is emerging as a disease which is of signiﬁcant economic con-
sequence to the poultry industry [7,8]. The disease can occur in at
least two forms. The acute form of NE typically results in mortal-
ity during the last weeks of rear of broilers (week 5–6). However,
many cases of NE are associated with relatively mild clinical signs
[9–11]. This subclinical form of NE results in decreased digestion
and absorption of feedstuffs and consequently reduced weight gain
[12,13]. At least in Europe it is now believed that the subclinical NE
is the most frequent form of the disease and causes the greatest
economic losses to the poultry production industry [14].
Although it is clear that C. perfringens is the etiologic agent of NE,
a wide range of host and pathogen factors can inﬂuence the severity
of the disease. These factors include the nature of the feedstuff, co-
infection with various Eimeria species and the molecular makeup
of C. perfringens in the gut [15]. Often these factors interact with
each other, and this has made the development of reliable infec-
tion models difﬁcult [15]. The molecular basis of virulence of C.
perfringens associated with NE is still being investigated. However,
almost all C. perfringens isolates from cases of NE possess the netB
gene [4,16,17] which encodes necrotic enteritis toxin B (NetB), a
-pore-forming toxin [6,18]. Pore formation by NetB can lead to
cell lysis by disruption of membrane integrity and a netB mutant of
C. perfringens is reported to be incapable of causing NE [6]. There
reserved.
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s also accumulating evidence that other virulence factors, such
s the TpeL toxin, play a role in disease [19]. The production of
hese virulence factors might explain the reported ability of some
etB-negative strains of C. perfringens to cause NE [4,6].
Immunisation with either crude toxoids [20] or culture super-
atants [21] can provide signiﬁcant but incomplete protection
gainst experimental NE. Although these vaccines are simple to
repare they suffer from the limitation that it is difﬁcult to con-
gure them for non-invasive dosing, for example by oral delivery.
ther workers have explored the possibility of a sub-unit which is
ble to protect against NE, with a view towards both improving vac-
ine efﬁcacy and opening the possibility of oral delivery. To date, a
ange of proteins derived from C. perfringens have been evaluated
s sub-unit vaccines including alpha-toxin, glyceraldehyde-3-
hosphate dehydrogenase, pyruvate-ferredoxin oxidoreductase,
ructose 1,6-biphosphate-aldolase, or a hypothetical protein [22].
mmunisation with any of these sub-units provided partial pro-
ection against experimental NE. Partial protection against NE has
lso been reported after immunisation with C. perfringens large
ytotoxin TpeL, endo-beta-N-acetylglucosaminidase or phospho-
lyceromutase [23]. A more recent study in which alpha-toxin,
etB, pyruvate-ferredoxin oxidoreductase and elongation factor-
u were compared as protective antigens concluded that NetB
nd pyruvate-ferredoxin oxidoreductase given with ISA71 adju-
ant provided enhanced protective immunity [24]. However, it is
nlikely that a licensed vaccine for widespread use could contain
ctive toxins. Therefore, there is a need to identify non-toxic vari-
nts of these toxins.
In a previous study, mutational analysis of NetB led to the iden-
iﬁcation of several amino acids important for toxicity [18]. The
utation of tryptophan to alanine at position 262 (W262A) resulted
n a signiﬁcant reduction in cytotoxicity towards LMH cells, bind-
ng to LMH  cells and haemolytic activity on red blood cells [18]. The
262A mutation is located within the rim domain of NetB, a region
ediating binding of the toxin to the cell membrane.
In this study, we investigated whether a formaldehyde NetB
oxoid or a NetB mutant (W262A) were able to induce protection
gainst experimental NE in poultry.
. Materials and methods
.1. Bacterial strains and plasmids
Plasmid pBAD (Invitrogen, Paisley, UK) was used as expression
ector and E. coli TOP10 (Invitrogen, Paisley, UK) as expression
ost. E. coli strains were grown either in Terriﬁc Broth (TB) or
uria–Bertani (LB) agar supplemented with ampicillin (100 g/ml)
t 37 ◦C and shaken at 300 rpm, where appropriate.
.2. Animals and housing conditions
Ross 308 broiler chickens were obtained as one-day-old chicks
rom Vervaeke-Belavi Hatchery (Tielt, Belgium, BE3031) and the
arent ﬂock had not been vaccinated with the commercial Net-
ax or any other C. perfringens vaccine. All animals were housed
n the same room. The birds were reared in pens at a density of
7 animals per 1.5 m2 on wood shavings. All pens were separated
y solid walls to prevent contact between birds from different
reatment groups. Before the trial, the rooms were decontami-
ated with Metatectyl HQ (Clim’oMedic®, Metatecta, Belgium) and
 commercial anticoccidial disinfectant (OOCIDE, DuPont Animal
ealth Solutions, Wilmington, USA). The chickens received ad libi-
um drinking water and feed. A 23 h/1 h light/darkness programme
as applied. The animal experiments were carried out accord-
ng to the recommendations and following approval of the Ethicalccine 31 (2013) 4003– 4008
Committee of the Faculty of Veterinary Medicine, Ghent University,
Belgium.
2.3. Expression and puriﬁcation of NetB and NetB W262A
The expression of wild type NetB or NetB W262A, without their
native signal peptides and with N-terminal His-tags for puriﬁca-
tion, was carried out in E. coli TOP10 cells and puriﬁcation was
carried out as described previously [18]. In summary, the recombi-
nant E. coli carrying the pBAD-NetB expression vector was grown
in TB to an optical density (OD595nm) of 0.5 and expression of the
toxin induced for 6 h by adding arabinose at a ﬁnal concentration
of 0.02% (w/v). Bacterial cells were harvested by centrifugation,
lysed enzymatically using BugBuster (Invitrogen, Paisley, UK), and
NetB puriﬁed by Ni-NTA chromatography columns (GE Healthcare
Life Sciences, Little Chalfont, UK) according to the manufacturer’s
instructions. The protein was  transferred into Tris-buffered saline
(TBS; 20 mM Tris pH 7.5, 150 mM NaCl) using PD-10 desalting
columns (GE Healthcare Life Sciences, Little Chalfont, UK) and pro-
tein concentrations measured with a UV–vis spectrophotometer
(Thermo Scientiﬁc, Cramlington, UK).
2.4. Preparation of formaldehyde NetB toxoid
Wild type NetB was  suspended at 400 g/ml in TBS and
formaldehyde added to a ﬁnal concentration of 130 mM.  After incu-
bation for 5 days at 37 ◦C, the reaction was stopped by the addition
of l-lysine (30 mM ﬁnal concentration) and residual formalde-
hyde was  removed by dialysis overnight against TBS by using
10 kDa MWCO  Spectra/Por 6 dialysis tubing (Spectrumlabs, Rancho
Dominguez, USA).
2.5. SDS-PAGE analysis
Protein purity was  analysed by SDS-PAGE on precast 4–12%
acrylamide-bisacrylamide gels (Invitrogen, Paisley, UK). Therefore,
gels were run in MES  running buffer (Invitrogen, Paisley, UK) for
45 min  at 200 V and stained with SimplyBlue (Invitrogen, Paisley,
UK). The Perfect Protein Marker (Merck, Darmstadt, Germany) was
used as a protein standard.
2.6. Cytotoxic activity of NetB and NetB toxoids
Wild type NetB or NetB toxoids were evaluated for cytotoxic-
ity towards a chicken hepatocellular carcinoma epithelial cell line
(LMH; ATCC: CRL-2117; ATCC-LGC Standards, Teddington, UK) as
described previously [18]. Brieﬂy, LMH  cells were grown on 96-
well plates to approximately 70% conﬂuency in Waymouth’s MB
752/1 medium (Invitrogen, Paisley, UK) supplemented with 10%
foetal calf serum in a 5% CO2 incubator at 37 ◦C. Subsequently,
cells were incubated with 100 l (0.4 mg/ml) of either wild type
NetB, formaldehyde NetB toxoid, or NetB W262A for 1 h at 37 ◦C.
Effects on cell morphology were observed with the Inverso-TC opti-
cal microscope (Medline Scientiﬁc, Chalgrove, UK) and images were
taken with the PowerShot S5 IS digital camera (Canon, Reigate, UK).
2.7. Measurement of antibody to NetB using ELISA
Antibody responses to NetB toxoids were determined using an
enzyme-linked immunosorbent assay (ELISA). Three groups 10 of
one-day-old Ross 308 broiler chickens were fed a wheat/rye-based
(43%/7.5%) diet, with soybean meal (24.6% and 25.3% soybean meal
in the starter and grower diet respectively) as a protein source [25].
On days 3, 9, and 15, animals were each immunised with 30 g of
either formaldehyde NetB toxoid or NetB W262A. Quil-A (50 g;
S.P. Fernandes da Costa et al. / Vaccine 31 (2013) 4003– 4008 4005
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3ig. 1. Experimental design of the in vivo NE model. Animals were immunised with f
ith  C. perfringens strain 56 on days 17, 18, 19, and 20. Animals were culled, necrop
renntag Biosector, Frederikssund, Denmark) was  used as an adju-
ant. The mixture was diluted in PBS to a total volume of 200 l,
ixed by pipetting and ﬁlter-sterilised (0.2 m pore size). Birds
ere vaccinated subcutaneously in the neck with a 200 l dose.
ontrols consisted of a group receiving only the Quil-A (50 g)
djuvant. Serum samples were taken on day 15 (prior to third
mmunisation) and on day 23.
For each ELISA, assays were performed in triplicate in three inde-
endent experiments, individual sera in each group were pooled
nd used at a dilution of 1:20. First, 96-well microtitre plates
Nunc-Immuno Plates–MaxiSorp; Thermo Scientiﬁc, Cramlington,
K) were coated with 2.5 g/well of puriﬁed NetB overnight at
◦C. Plates were washed three times with TBS-T (TBS, Tween 0.05%,
/v) and blocked with Odyssey blocking buffer (LI-COR Biosciences,
ambridge, UK) for 1 h at room temperature. Plates were washed
ith TBS-T and 100 l/well of pooled sera was incubated for 2 h
t room temperature. Bound antibodies were detected using a
RP-conjugated rabbit anti-chicken IgY (H + L) secondary antibody
1:5000; Thermo Scientiﬁc, Cramlington, UK) and the ELISA HRP
ubstrate (680) pack (LI-COR Biosciences, Cambridge, UK). Fluores-
ent intensity was imaged using the Odyssey CLX infrared imaging
ystem (LI-COR Biosciences, Cambridge, UK). The ﬂuorescence val-
es for each sample were normalised by subtracting the values
btained for using TBS as a sample.
.8. In vivo NE model
The NE model was based on the subclinical in vivo model
escribed previously [25,26]. Groups of 25–28 one-day-old Ross
08 broiler chickens were immunised three times with either
ormaldehyde NetB toxoid formulated with Quil-A or NetB W262A
ormulated with Quil-A as described above. Controls consisted of
n untreated group and a group receiving only the adjuvant. Nobilis
umboro D 78 vaccine (Schering-Plough Animal Health, Brussels,
elgium) was given in the drinking water on day 16. From day 17
nwards soy bean meal was replaced by ﬁshmeal (30%) as a pro-
ein source. All groups were challenged orally, using a plastic tube
nserted in the crop, on days 17, 18, 19 and 20 with a single dose
f approximately 4 × 108 cfu of C. perfringens strain 56. On day 18,
ll animals were orally inoculated with a 10× dose of Paracox-5
Schering-Plough Animal Health, Brussels, Belgium) [26]. On days
1, 22, and 23, one-third of the birds in each group were euthanised
nd necropsied. A schematic outline of the experimental design is
hown in Fig. 1.
.9. Assessment of protection
NE severity was assessed by scoring lesions within the small
ntestine of each animal (duodenum to ileum) as described by
eyburn et al. [27] as follows: 0 = no gross lesions; 1 = congested
ntestinal mucosa; 2 = focal necrosis or ulceration (1–5 foci);
 = focal necrosis or ulceration (6–15 foci); 4 = focal necrosisdehyde NetB toxoid or NetB W262A on days 3, 9, and 15 post-hatching and infected
and scored for lesions within the small intestines on days 21, 22, or 23.
or ulceration (≥16 foci); 5 = patches of necrosis 2–3 cm long;
6 = diffuse necrosis typical of ﬁeld cases. Animals showing lesion
scores of 2 or higher were classiﬁed as NE positive.
3. Statistical analysis
For the in vivo NE model, differences within the occurrence
of NE-positive animals between the controls and the NetB toxoid
vaccinated groups were evaluated by a binary logistic regression
analysis with the SPSS Statistics software 21.0 (SPSS Inc., Chicago,
USA). A 2-way ANOVA analysis with the GraphPad Prism software
5.01 (GraphPad Software, La Jolla, USA) was used to compare the
means of ELISA data. In both analysis, a p value of less than 0.01
was considered as signiﬁcant (***p < 0.001; **p < 0.01).
4. Results
4.1. SDS-PAGE analyses of NetB W262A and formaldehyde NetB
toxoid
Puriﬁed NetB W262A was  analysed by SDS-PAGE (supplemental
Fig. 1A). The predicted molecular size of monomeric NetB, without
its native signal peptide but with an N-terminal His-tag, is 37.6 kDa
and we observed a major band with an apparent molecular size of
approximately 38 kDa. A lower abundance protein migrated with a
molecular weight of greater than 200 kDa and this is likely to be the
SDS-resistant heptameric form of the toxin [18]. We  also prepared a
formaldehyde NetB toxoid. The toxoid migrated as a high molecular
complex on SDS-PAGE (supplemental Fig. 1B), consistent with the
chemical cross-linking of individual proteins.
Supplementary data related to this article found, in the online
version, at http://dx.doi.org/10.1016/j.vaccine.2013.05.063.
4.2. Cytotoxic activity of NetB and NetB toxoids on LMH  cells
LMH  cells were incubated with 0.4 mg/ml  wild type NetB or
NetB toxoids for 1 h at 37 ◦C and any morphological changes
observed by optical microscopy (supplemental Fig. 2). Untreated
cells showed epithelial and dendritic-like growth (supplemental
Fig. 2A), whereas treatment of cells with puriﬁed wild type NetB
caused cell blebbing and cell swelling (supplemental Fig. 2B). Incu-
bation with formaldehyde NetB toxoid or NetB W262A did not
result in any morphological changes indicative of toxicity to LMH
cells (supplemental Fig. 2C and D, respectively).
Supplementary data related to this article found, in the online
version, at http://dx.doi.org/10.1016/j.vaccine.2013.05.063.
4.3. Measurement of antibody to NetB using ELISAWe used an ELISA to measure the antibody responses to NetB
in immunised chicken (Fig. 2). Animals immunised with either
formaldehyde NetB toxoid or NetB W262A showed an increasing
4006 S.P. Fernandes da Costa et al. / Va
Fig. 2. Measurement of antibody to NetB using ELISA. Chicken were immunised
with either formaldehyde NetB toxoid, NetB W262A or the Quil-A adjuvant alone,
on  days 3, 9, and 15. Sera were taken on day 15 (prior to third immunisation) and on
day  23. The graph represents data from three replicates in three independent exper-
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ifference (***p < 0.001; 2-way ANOVA analysis) relative to the Quil-A immunised
ontrol.
ntibody response to NetB over the course of the immunisation
chedule. By day 23 poultry immunised with the toxoids showed
igniﬁcantly higher levels (p < 0.001) of circulating antibody than
ontrol animals immunised with Quil-A alone. In addition, on day
3 animals immunised with the NetB W262A showed signiﬁcantly
ncreased (p < 0.01) NetB antibody responses than the group vacci-
ated with the formaldehyde NetB toxoid.
.4. Protection against experimental NE after immunisation with
ormaldehyde NetB toxoid or NetB W262A
Immunisation with either the formaldehyde NetB toxoid or with
etB W262A reduced lesion scores relative to the control groups in
oultry experimentally infected with C. perfringens (Fig. 3A). In the
ontrol groups of untreated chickens, or chickens dosed with adju-
ant only, the mean lesion scores were 1.04 and 1.07, respectively.
n contrast, animals immunised with the formaldehyde NetB toxoid
howed a mean lesion score of 0.33 and animals immunised with
etB W262A a mean lesion score of 0.25. There was also a reduced
ccurrence of NE-positive chicken in vaccinated groups compared
ith control groups (Fig. 3B). In the non-vaccinated and the adju-
ant only immunised groups 48% of the birds were NE-positive,
hereas in animals vaccinated with formaldehyde NetB toxoid or
etB W262A only 15% and 11% of animals were NE-positive, respec-
ively.
. Discussion
In broilers, acute NE is often evidenced as a sudden increase in
ock mortality during the last weeks of the rearing period (week
–6) and at necropsy large necrotic foci and extensive necrosis are
ound at the mucosal surface of the gut. The infection model we
ave used in our study reﬂects the subclinical form of disease. In
ur model approximately 50% of the control animals develop focal
esions which are typical of the lesions seen in ﬁeld cases of sub-
linical NE. We  do not observe massive necrosis of the gut which
s associated with acute disease. In previous studies we  have used
his model, in some cases with minor modiﬁcations, to evaluate
he effect of feed additives, vaccines or antibiotics on disease or to
erform studies on the pathogenesis of NE [21,26,28–30].
Recently, we have solved the heptameric pore-forming struc-
ure of NetB and determined the roles of selected amino acids
ediating binding and toxicity to target cells [18]. The NetB mutant
W262A) showed the greatest reduction in binding and toxicity,
elative to wild type NetB. Cytotoxicity of wild type NetB and
etB W262A on LMH  cells was tested via the release of lactateccine 31 (2013) 4003– 4008
dehydrogenase (LDH) into the culture medium [18]. Wild type
NetB caused LDH release and the median cytotoxic dose (CT50) was
800 nM.  In contrast, LDH release could not be detected after incu-
bation of cells with NetB W262A, even at a concentration of 4 M
[18].
This study was  conducted to test NetB W262A or a formalde-
hyde NetB toxoid for their potential to induce an immune response
able to protect chicken against the subclinical form of NE. Vaccina-
tion with either antigen increased the antibody response to NetB,
relative to the control groups. In addition, antibody levels to NetB
were signiﬁcantly higher on day 23 for the NetB W262A immunised
group than for the formaldehyde NetB toxoid vaccinated group. As
expected, control chickens did not have high levels of antibody to
NetB on days 15 and 23 of our study. We  recorded an induced pro-
tection after immunisation with either of the NetB toxoids in our
NE disease model. However, a direct comparison with protection
studies carried out by other researchers with different antigens
is difﬁcult, due to differences in the immunisation regimens and
disease models used.
Although our ﬁndings are encouraging, the vaccination schedule
we have reported here would not be suitable for widespread use in
poultry ﬂocks. The lifespan of broiler poultry is typically 4–8 weeks
and using our immunisation schedule we could not detect a signiﬁ-
cant increase in serum NetB antibody at 15 days post immunisation.
Protection of younger animals might be achieved by the vaccination
of breeder hens with the subsequent transfer of maternal antibody
to eggs [31,32], by in ovo immunisation [33,34], or using a vaccine
delivery system that results in a rapid development of immunity
[35].
We  could not demonstrate complete protection of poultry
after immunisation with either NetB W262A or the formaldehyde
NetB toxoid. It is possible that NetB variants with mutations in
other residues might lead to higher levels of protection. However,
our ﬁndings that immunisation with either NetB W262A or the
formaldehyde toxoid induced broadly similar levels of protection
suggests that it is more likely that delivery with a different adju-
vant or by a different route is required for improved protective
immunity. If NetB is directly responsible for the gut lesions seen in
diseased animals, then it is possible that immunisation by a route
that would induce a mucosal antibody response would provide
increased protection against NE. Immunisation with an attenu-
ated strain of Salmonella enterica serovar Typhimurium expressing
NetB W262A could result in the induction of mucosal antibody
which would then protect the gut mucosal surface from the toxin.
The use of a Salmonella-vectored vaccine might also allow a sin-
gle dose of vaccine to be given – an important consideration
when immunising poultry ﬂocks. Previously, other workers have
expressed C. perfringens fructose-biphosphate-aldolase, pyruvate-
ferredoxin oxidoreductase, hypothetical protein, or alpha-toxoid
in attenuated strains of S. enterica serovar Typhimurium and have
reported the induction of protective immunity against experi-
mental NE [36,37]. These Salmonella based vaccines have been
given to poultry orally and immunisation resulted in both serum
and mucosal antibody responses to the C. perfringens antigens
[36,37].
Alternatively, we have previously reported the expression of
alpha-toxoid on the surface of Bacillus subtilis spores, and these
spores have been shown to be immunogenic in mice, inducing
mucosal antibody responses after oral dosing [38]. The immuno-
genicity of the recombinant spores in poultry has not been
investigated. However, B. subtilis spores have been shown to
be effective as competitive exclusion agents in poultry, limiting
colonisation of the gut by C. perfringens [39]. Oral dosing with B.
subtilis spores expressing NetB W262A might therefore offer short
term beneﬁts as the spores act as competitive exclusion agents and
also induce protective antibody responses in the longer term.
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Fig. 3. In vivo NE model. (A) Lesion scores of individual broiler chickens. According to severity, lesions in the small intestine were scored from 0 (no gross lesions) to 6
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An alternative approach to devising an NE vaccine that pro-
ides more complete protection against disease might lie in
sing a combination of protective antigens, such as NetB toxoid
ith alpha-toxoid, glyceraldehyde-3-phosphate dehydrogenase,
yruvate-ferredoxin oxidoreductase, fructose 1,6-biphosphate-
ldolase, hypothetical protein, elongation factor-Tu, TpeL, endo-
eta-N-acetylglucosaminidase, or phosphoglyceromutase which
ave all been shown to provide partial protection against disease.
In conclusion, this study demonstrates that a formaldehyde
etB toxoid or NetB W262A could be used in subsequent work to
evise a vaccine to control NE. Compared to the production method
f formaldehyde NetB toxoid, the NetB W262A mutant is easily
roduced in E. coli. In addition, toxoiding using formaldehyde can
how batch to batch variation and reversion to toxicity has been
eported in other bacterial toxins in the past [40,41]. Furthermore,
t is important to minimise any free formaldehyde in vaccine prepa-
ations to avoid possible side effects [42]. As a NetB formaldehyde
oxoid might suffer from these problems, the use of a NetB mutant
ould allow a more reliable and simple production of a vaccine.
owever, further work is required to establish how such a toxoid
accine could be effectively delivered, suitable for use in the poultry
ndustry.
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